Lee Financial Co Has $277,000 Holdings in Pfizer Inc. $PFE

Lee Financial Co cut its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,940 shares of the biopharmaceutical company’s stock after selling 635 shares during the period. Lee Financial Co’s holdings in Pfizer were worth $277,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. William B. Walkup & Associates Inc. boosted its position in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co grew its stake in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC lifted its position in Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 472 shares during the last quarter. Bellevue Group AG boosted its holdings in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after acquiring an additional 485 shares during the period. Finally, MSH Capital Advisors LLC grew its position in shares of Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 485 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.2%

Shares of NYSE PFE opened at $25.16 on Monday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business has a fifty day moving average of $24.60 and a two-hundred day moving average of $24.42. The stock has a market cap of $143.05 billion, a PE ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several research firms recently weighed in on PFE. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research increased their price objective on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Bank of America boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.